Rocket Pharmaceuticals secures $180M cash injection via regulatory voucher sale
Rocket Pharmaceuticals (NASDAQ:RCKT) completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), generating $180 million in gross, non-dilutive cash proceeds.
The transaction capitalizes on a high-value regulatory asset to materially strengthen the commercial-stage biotechnology company's balance sheet without diluting current public equity holders.
The FDA originally awarded the voucher to Rocket in March 2026 concurrently with the regulatory approval of KRESLADI, the company's autologous gene therapy engineered to treat severe leukocyte adhesion deficiency-I (LAD-I).
LAD-I is an ultra-rare, life-threatening primary immunodeficiency that leaves pediatric patients highly susceptible to severe, recurrent bacterial and fungal infections.
The FDA's PRV program provides transferable vouchers to companies developing therapies for rare pediatric conditions, which can later be sold to other drug manufacturers to shorten an experimental drug's regulatory review timeline from ten months to six months.
The cash injection significantly alters Rocket's near-term capital profile and funding timeline.
The company previously reported holding cash, cash equivalents, and investments totaling $144.4 million as of March 31, 2026.
By incorporating the $180 million in proceeds from this transfer, the company's pro forma cash and liquid investment balance rises to approximately $322.6 million.
Management confirmed that this expanded capital base is projected to fully fund internal operations, pipeline manufacturing, and commercial launch activities for KRESLADI into the second quarter of 2028.
